Agent used as first-line therapy | |||
---|---|---|---|
Thiopurines (n=77) | Anti-TNF-α (n=11) | Combination therapy (n=13) | |
Median interval between surgery and starting therapy | 15 weeks (3–210) | 17 weeks (4–35) | 12 weeks (6–156) |
Exposure to same treatment before surgery | 45 (58.4%) | 9 (81.8%) | 3 (23.1%) |
Intolerance | 18 (23.4%) | 1 (9.1%) | 1 (7.7%) |
Treatment success | 32 (41.6%) | 5 (45.5%) | 11 (84.6%)* |
Death | 1 (1.3%) | 0 (0%) | 0 (0%) |
Non-response | |||
1° | 11 (14.3%) | 0 (0%) | 1 (7.7%) |
2° | 11 (14.3%) | 5 (45.5%) | 2 (15%)* |
Required second resection before end of follow-up | 3 (3.9%) | 0 (0%) | 0 (0%) |
Required glucocorticosteroids | 20 (26%) | 3 (27.3%) | 1 (7.7%) |
Lost to follow-up | 4 (5.2%) | 0 (0%) | 0 (0%) |
*Two patients progressed with perianal disease on treatment, although remaining in remission luminally.
TNF, tumour necrosis factor.